Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, announces a majority investment by Curewell Capital (“Curewell”), a Los Angeles-based private equity firm focused on building industry-leading healthcare companies. Founded in 2003, WPT has built extensive expertise across hundreds of novel drug substance programs, spanning complex synthesis, medicinal chemistry, scale-up, and GMP supply. Headquartered at its 54-acre campus in Delaware, WPT operates two adjacent state-of-the-art facilities with extensive cGMP manufacturing capabilities.
Read the full article: Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital //
Source: https://www.businesswire.com/news/home/20251021135557/en/Wilmington-PharmaTech-Continues-Expansion-with-Significant-Investment-from-Curewell-Capital